Shanghai Junshi Biosciences Co Ltd
SSE:688180
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.86
48.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Shanghai Junshi Biosciences Co Ltd
Revenue
Shanghai Junshi Biosciences Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai Junshi Biosciences Co Ltd
SSE:688180
|
Revenue
ÂĄ1.9B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
ÂĄ27.2B
|
CAGR 3-Years
53%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
ÂĄ11.4B
|
CAGR 3-Years
36%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Revenue
ÂĄ2.1B
|
CAGR 3-Years
111%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
ÂĄ2.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Revenue
ÂĄ1.9B
|
CAGR 3-Years
291%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shanghai Junshi Biosciences Co Ltd
Glance View
Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. emerged as a dynamic player in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of innovative therapies. This company, based in Shanghai, China, has carved a niche in the highly competitive field through its robust pipeline of monoclonal antibodies, small molecule drugs, and therapeutic vaccines. Junshi Biosciences prides itself on its comprehensive R&D capabilities, operating state-of-the-art research facilities that foster significant scientific advancements. Central to its growth strategy is an ongoing commitment to addressing unmet medical needs in oncology, autoimmune, metabolic diseases, and beyond, positioning itself at the forefront of precision medicine. Junshi Biosciences generates revenue through a multifaceted business model that includes partnering with top-tier global pharmaceutical companies, engaging in strategic licensing agreements, and advancing its proprietary products through various stages of clinical trials to eventual market launch. A landmark achievement for the company was the development and commercialization of Toripalimab, China's first domestically developed anti-PD-1 monoclonal antibody approved for multiple indications, which marked a significant milestone in its financial trajectory. Such breakthroughs not only bolster its top-line revenue but also solidify its reputation as an innovator in the global biotechnology landscape. By blending scientific ingenuity with strategic collaborations, Junshi continues to expand its international footprint and deepen its impact on global health.
See Also
What is Shanghai Junshi Biosciences Co Ltd's Revenue?
Revenue
1.9B
CNY
Based on the financial report for Dec 31, 2024, Shanghai Junshi Biosciences Co Ltd's Revenue amounts to 1.9B CNY.
What is Shanghai Junshi Biosciences Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
20%
Over the last year, the Revenue growth was 30%. The average annual Revenue growth rates for Shanghai Junshi Biosciences Co Ltd have been -21% over the past three years , 20% over the past five years .